Does Treatment of Ocular Myasthenia Gravis With Early Immunosuppressive Therapy Prevent Secondarily Generalization and Should It Be Offered to All Such Patients?

J Neuroophthalmol. 2016 Mar;36(1):98-102. doi: 10.1097/WNO.0000000000000270.
No abstract available

MeSH terms

  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Myasthenia Gravis / drug therapy*
  • Myasthenia Gravis / prevention & control
  • Secondary Prevention

Substances

  • Immunosuppressive Agents